  The recent global surge in COVID-19 infections has been fueled by new
SARS-CoV-2 variants, namely Alpha, Beta, Gamma, Delta, etc. The molecular
mechanism underlying such surge is elusive due to 4,653 non-degenerate
mutations on the spike protein, which is the target of most COVID-19 vaccines.
The understanding of the molecular mechanism of transmission and evolution is a
prerequisite to foresee the trend of emerging vaccine-breakthrough variants and
the design of mutation-proof vaccines and monoclonal antibodies. We integrate
the genotyping of 1,489,884 SARS-CoV-2 genomes isolates, 130 human antibodies,
tens of thousands of mutational data points, topological data analysis, and
deep learning to reveal SARS-CoV-2 evolution mechanism and forecast emerging
vaccine-escape variants. We show that infectivity-strengthening and
antibody-disruptive co-mutations on the S protein RBD can quantitatively
explain the infectivity and virulence of all prevailing variants. We
demonstrate that Lambda is as infectious as Delta but is more
vaccine-resistant. We analyze emerging vaccine-breakthrough co-mutations in 20
countries, including the United Kingdom, the United States, Denmark, Brazil,
and Germany, etc. We envision that natural selection through infectivity will
continue to be the main mechanism for viral evolution among unvaccinated
populations, while antibody disruptive co-mutations will fuel the future growth
of vaccine-breakthrough variants among fully vaccinated populations. Finally,
we have identified the co-mutations that have the great likelihood of becoming
dominant: [A411S, L452R, T478K], [L452R, T478K, N501Y], [V401L, L452R, T478K],
[K417N, L452R, T478K], [L452R, T478K, E484K, N501Y], and [P384L, K417N, E484K,
N501Y]. We predict they, particularly the last four, will break through
existing vaccines. We foresee an urgent need to develop new vaccines that
target these co-mutations.
